Tags

Type your tag names separated by a space and hit enter

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders.
Drugs. 1996 Feb; 51(2):260-77.D

Abstract

Ebastine is a long-acting nonsedating second generation histamine H1 receptor antagonist which binds preferentially to peripheral H1 receptors in vivo. It has shown antihistamine and antiallergic activity in healthy volunteers and patients with allergies, and protected against histamine-induced bronchoconstriction in patients with asthma. Significant symptom improvement is observed in patients with seasonal or perennial allergic rhinitis or chronic idiopathic urticaria following administration of ebastine 10 mg/day, or 20 mg/day in severe rhinitis. In clinical trials, the efficacy of ebastine 10 or 20 mg/day was generally similar to standard dosages of terfenadine, cetirizine, astemizole and loratadine in patients with seasonal allergic rhinitis, astemizole, terfenadine and ketotifen in patients with chronic idiopathic urticaria, and ketotifen, terfenadine, chlorpheniramine and mequitazine in patients with perennial allergic rhinitis. The most frequent adverse events reported during ebastine therapy are drowsiness, headache and dry mouth, the incidence being similar to that reported in placebo recipients. Serious adverse cardiac events, observed on rare occasions with some other histamine H1 receptor antagonists, have not been reported with ebastine, and there has been no evidence of QTc interval prolongation related to ebastine therapy. Thus, once-daily ebastine offers an effective and well-tolerated alternative to other second generation antihistamines in current use for the first-line treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Authors+Show Affiliations

Adis International Limited, Auckland, New Zealand.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8808167

Citation

Wiseman, L R., and D Faulds. "Ebastine. a Review of Its Pharmacological Properties and Clinical Efficacy in the Treatment of Allergic Disorders." Drugs, vol. 51, no. 2, 1996, pp. 260-77.
Wiseman LR, Faulds D. Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs. 1996;51(2):260-77.
Wiseman, L. R., & Faulds, D. (1996). Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs, 51(2), 260-77.
Wiseman LR, Faulds D. Ebastine. a Review of Its Pharmacological Properties and Clinical Efficacy in the Treatment of Allergic Disorders. Drugs. 1996;51(2):260-77. PubMed PMID: 8808167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. AU - Wiseman,L R, AU - Faulds,D, PY - 1996/2/1/pubmed PY - 1996/2/1/medline PY - 1996/2/1/entrez SP - 260 EP - 77 JF - Drugs JO - Drugs VL - 51 IS - 2 N2 - Ebastine is a long-acting nonsedating second generation histamine H1 receptor antagonist which binds preferentially to peripheral H1 receptors in vivo. It has shown antihistamine and antiallergic activity in healthy volunteers and patients with allergies, and protected against histamine-induced bronchoconstriction in patients with asthma. Significant symptom improvement is observed in patients with seasonal or perennial allergic rhinitis or chronic idiopathic urticaria following administration of ebastine 10 mg/day, or 20 mg/day in severe rhinitis. In clinical trials, the efficacy of ebastine 10 or 20 mg/day was generally similar to standard dosages of terfenadine, cetirizine, astemizole and loratadine in patients with seasonal allergic rhinitis, astemizole, terfenadine and ketotifen in patients with chronic idiopathic urticaria, and ketotifen, terfenadine, chlorpheniramine and mequitazine in patients with perennial allergic rhinitis. The most frequent adverse events reported during ebastine therapy are drowsiness, headache and dry mouth, the incidence being similar to that reported in placebo recipients. Serious adverse cardiac events, observed on rare occasions with some other histamine H1 receptor antagonists, have not been reported with ebastine, and there has been no evidence of QTc interval prolongation related to ebastine therapy. Thus, once-daily ebastine offers an effective and well-tolerated alternative to other second generation antihistamines in current use for the first-line treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. SN - 0012-6667 UR - https://www.unboundmedicine.com/medline/citation/8808167/Ebastine__a_review_of_its_pharmacological_properties_and_clinical_efficacy_in_the_treatment_of_allergic_disorders_ L2 - https://dx.doi.org/10.2165/00003495-199651020-00006 DB - PRIME DP - Unbound Medicine ER -